Volume 9 Supplement 3
Edited by Howard Fillit and Antony Horton
The conference and the publication of these proceedings were supported by a conference grant: U13-AG031125 from the National Institute of Aging and the National Institute for Neurological Disorders and Stroke. Additional support was provided by CoMentis, Inc; Pfizer, Inc.; Biogen Idec and Boehringer Ingelheim Pharmaceuticals, Inc.
2007 and 2008 Drug Discovery for Neurodegeneration Conference. Go to conference site.
New York, USA. 5-6 February 2007Washington, DC, USA. 4-5 February 2008
Despite rapid progress in our understanding of disease mechanisms and an exploding list of new targets for therapeutic intervention, drug discovery and development remains a highly risky business. Understandin...
Citation: BMC Neuroscience 2008 9(Suppl 3):S1
Development of therapeutics for the central nervous system is one of the most challenging areas in drug development. This is primarily because, in addition to all of the other complications one faces in develo...
Citation: BMC Neuroscience 2008 9(Suppl 3):S2
NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ), an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP), exhibits some structu...
Citation: BMC Neuroscience 2008 9(Suppl 3):S3
Nanotechnologies are materials and devices that have a functional organization in at least one dimension on the nanometer (one billionth of a meter) scale, ranging from a few to about 100 nanometers. Nanoengin...
Citation: BMC Neuroscience 2008 9(Suppl 3):S4
Intranasal delivery provides a practical, non-invasive method of bypassing the blood-brain barrier (BBB) to deliver therapeutic agents to the brain and spinal cord. This technology allows drugs that do not cro...
Citation: BMC Neuroscience 2008 9(Suppl 3):S5
This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeuticall...
Citation: BMC Neuroscience 2008 9(Suppl 3):S6
A drug candidate suitable for clinical testing is expected to bind selectively to the receptor site on the target, to elicit the desired functional response of the target molecule, and to have adequate bioavai...
Citation: BMC Neuroscience 2008 9(Suppl 3):S7
Speed
63 days to first decision for reviewed manuscripts only
44 days to first decision for all manuscripts
193 days from submission to acceptance
12 days from acceptance to publication
Citation Impact
3.288 - 2-year Impact Factor
3.316 - 5-year Impact Factor
1.011 - Source Normalized Impact per Paper (SNIP)
1.168 - SCImago Journal Rank (SJR)
Usage
1,012,319 Downloads
120 Altmetric Mentions